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Abstract
Background
Systemic lupus erythematosus (SLE) is associated with severe cardiovascular complica-
tions. The T50 score is a novel functional blood test quantifying calcification propensity in
serum. High calcification propensity (or low T50) is a strong and independent determinant of
all-cause mortality in various patient populations.
Methods
A total of 168 patients with 4 American College of Rheumatology (ACR) diagnostic criteria
from the Swiss Systemic lupus erythematosus Cohort Study (SSCS) were included in this
analysis. Serum calcification propensity was assessed using time-resolved nephelometry.
Results
The cohort mainly consisted of female (85%), middle-aged (43±14 years) Caucasians
(77%). The major determinants of T50 levels included hemoglobin, serum creatinine and
serum protein levels explaining 43% of the variation at baseline. Integrating disease activity
(SELENA-SLEDAI) into this multivariate model revealed a significant association between
disease activity and T50 levels. In a subgroup analysis considering only patients with active
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disease (SELENA-SLEDAI score4) we found a negative association between T50 and
SELENA-SLEDAI score at baseline (Spearman’s rho -0.233, P = 0.02).
Conclusions
Disease activity and T50 are closely associated. Moreover, T50 levels identify a subgroup of
SLE patients with ongoing systemic inflammation as mirrored by increased disease activity.
T50 could be a promising biomarker reflecting SLE disease activity and might offer an earlier
detection tool for high-risk patients.
Introduction
Patients with systemic lupus erythematosus (SLE), a chronic inflammatory autoimmune dis-
ease, suffer from a dramatically increased cardiovascular morbidity and mortality compared to
age- and gender matched individuals [1, 2]. Although the survival rates of patients with SLE
has considerably improved over the last decades, a large proportion of this excess risk is attrib-
utable to causes, which can be only partially explained by traditional cardiovascular risk factors
such as hypertension, hyperlipidemia, smoking, and obesity [3, 4]. Indeed, non-traditional car-
diovascular risk factors reflecting inflammation, disease activity or oxidative stress may con-
tribute to the increased cardiovascular risk in these patients [5–7].
Evidence from SLE animal models suggests that the degree of systemic inflammation corre-
lates with the development of atherosclerosis, and vascular damage [8, 9]. Accelerated vascular
micro-calcification, as a novel cellular, inflammation-driven pathway of arterial calcification,
represents an intriguing potential mechanism linking accelerated vascular damage to inflam-
mation and cardiovascular risk in SLE [10].
Fetuin-A is a potent regulator of extracellular matrix mineralization and the major serum-
based inhibitor of calcium phosphate precipitation [11]. Dysregulation of Fetuin-A levels has
been associated with increased systemic inflammation and pro-calcifying cytokine production
[12]. Indeed, pro-inflammatory cytokines are considered important promoters of vascular
smooth muscle cell osteochondrocytic transformation and mineralization [13]. Therefore,
identification of circulating biomarkers for this process and systematic testing of their links
with SLE disease activity and subsequent clinical cardiovascular events is of importance for
advancing knowledge in this area of clinical research.
The T50 score, which represents the maturation time of calciprotein particles, is a novel bio-
marker, validated for the determination of serum calcification propensity [14]. The T50-Test is
based on a nephelometric method allowing to quantify in-vitro the calcification inhibitory
capacity of serum under predefined conditions of rising calcium and phosphate concentra-
tions. A high calcification propensity (i.e. low T50) is associated with increased all-cause
mortality and outperforms the predictive value of traditional cardiovascular risk factors con-
cerning all-cause mortality in various patient populations with established chronic kidney dis-
ease (CKD) [15], on hemodialysis [16] and after kidney transplantation [17]. Furthermore,
low T50 values were closely associated with progressive stiffening of the aorta [15].
However, to date, there are no clinical studies, which have investigated whether T50 values
are associated with SLE disease activity. In this prospective study of SLE patients enrolled in
the Swiss Systemic lupus erythematosus Cohort Study (SSCS), we hypothesize that T50 values,
potentially as an indirect marker of systemic inflammation, are independently related to higher
disease activity and adverse cardiovascular events.
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Materials and methods
Patient population and study design
Our study population consists of SLE patients participating in the SSCS, a cooperative multi-
center study across various clinical disciplines (clinical immunology, internal medicine,
nephrology, rheumatology), in seven tertiary medical centers of Switzerland (Basel, Bern,
Geneva, Lausanne, St. Gallen, Schaffhausen and Zurich) [18]. Characteristics and treatment
modalities of the SSCS have been previously published [19]. SSCS has been approved by the
ethics committees of all involved institutions (i.e. Ethikkommission Nordwest- und Zen-
tralschweiz, Kantonale Ethikkommission Bern, Commission cantonale d’e´thique de la recher-
che Genève, Commission cantonale d’e´thique de la recherche sur l’être humain Vaud,
Ethikkommission Ostschweiz, Ethikkommission des Kantons Zu¨rich) and is in line with the
declaration of Helsinki. All subjects gave their written informed consent in the context of the
cohort study.
The present study was designed as a cross-sectional analysis of prospectively collected data
between April 2007 and December 2013. Out of 180 patients (>18 years old) with available
clinical, laboratory and baseline serum samples, 168 patients with 4 American College of
Rheumatology (ACR) diagnostic criteria shown in S1 Table were included in the final analysis.
Data regarding disease activity, biochemical characteristics, medication and cardiovascular
risk factors were extracted from the cohort database. Target organ damage and prior cardio-
vascular events were captured at baseline. Serum samples were collected from each participant
at cohort enrollment and were available for the calcification propensity (T50) assessment.
Definitions
Definitions of clinical terms (cardiovascular events) and assessment tools (ACR criteria, SELE-
NA-SLEDAI score, SLICC-DI) used throughout the manuscript are summarized in S2 Table.
SLE was diagnosed using the 1997 revised classification ACR criteria. Disease activity was
assessed by the “Safety of Estrogens in Lupus Erythematosus National Assessment—SLE Dis-
ease Activity Index” (SELENA-SLEDAI) (S2 Table) and a score 4 was considered as active
disease in accordance with the definition used by the group of Yee C-S et al. [20] and previous
analyses of the SSCS.
Organ damage was assessed by the Systemic Lupus International Collaborative Clinics/
American College of Rheumatology (SLICC/ACR) Damage Index (SLICC/DI) summarized in
S3 Table. A damage score of>1 was considered as severe damage while a score of 1 or lower
was thought to reflect mild or no damage at all. Cardiovascular morbidity was defined using
parameters exclusively recorded in the SLICC/DI-score summarized in S4 Table. Traditional
as well as non-traditional cardiovascular risk factors were evaluated according to established
definitions at each visit summarized in S5 Table. CKD, defined according to KDIGO 2012 cri-
teria shown in S6 Table, was also captured as a non-traditional cardiovascular risk factor.
Biochemical analyses
Serum samples were drawn from a peripheral vein in vacutainer tubes. After 30 to 60 minutes
samples were centrifuged at 4000 rpm (corresponding to 2600 G) for 15 min at ambient tem-
perature and the extracted serum was stored in aliquots and frozen at -80˚C until further use.
Serum calcification propensity was assessed using time-resolved nephelometry (BMG Labtech,
Offenburg, Germany) according to an already described methodology [14]. All serum samples
were measured under blinded conditions at the Department of Nephrology, Hypertension and
Clinical Pharmacology, University Hospital Bern, Bern, Switzerland. Data were processed by
Serum calcification propensity in patients with systemic lupus erythematodes
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calculating the precipitation time T50 from nonlinear regression curves. Samples were mea-
sured in triplicates. T50 is stable when samples were stored at -80˚C throughout as has been
demonstrated in previous studies [16]. Also no hemolytic sera were measured.
Statistical analysis
Data are presented as absolute numbers with percentages for categorical data, as
means ± standard deviation (SD) for continuous variables that were normally distributed and
as medians with interquartile range (IQR) for non-normally distributed data. Normality was
tested using the Kolmogorov-Smirnov test. A cross tabulation for comparison of all demo-
graphic, clinical and laboratory characteristics was performed across the 3 tertiles of serum
T50. P-value was calculated by one-way ANOVA test for continuous variables with normal dis-
tribution, Kruskal-Wallis test for continuous variables with non-normal distribution and chi-
squared test for categorical variables. Factors associated with baseline serum T50 were evalu-
ated using linear regression models. Only variables which were significantly different between
the 3 tertiles of serum T50 were analyzed. B-values were expressed per one SD increase in each
continuous independent variable. In case of increased co-linearity between variables, the vari-
able which conferred better to the R2 value was selected. After the conduction of multivariate
analysis, forced models were designed forcing activity (SLEDAI) and damage (SLICC) indexes
into the model. We also performed sensitivity analyses in various clinical, demographic and
activity score subgroups of patients to examine the association between serum calcification
propensity (T50 value) and several parameters. A p value < 0.05 was considered to indicate sta-
tistical significance with the exception of multiple comparisons, in which Bonferroni’s correc-
tion for multiple comparisons was applied and a p value < 0.016 (significant P value = P value
/ number of comparisons between groups = 0.05 / 3 = 0.016) was considered as significant; all
tests were two-sided. The IBM SPSS Statistics 20.0 statistical software package (SPSS Inc, Chi-
cago, Illinois, USA) was used for all calculations.
Results
Baseline characteristics
Serum T50 measured at baseline displayed near-normal distribution (Fig 1). The baseline
demographic, clinical and laboratory characteristics of all study individuals (n = 168) and
across tertiles of serum T50 are presented in Table 1. The cohort consisted mainly of female
(85%), middle-aged (43±14 years) outpatients of Caucasian origin (77%); 35% were over-
weight. The median (IQR) SLE-disease activity assessed by SELENA-SLEDAI score was 4 (7)
reflecting mildly active lupus with a mean disease duration of 7 (11) years. The organ damage
SLICC-DI score was low 0 (1) and the cohort exhibited a rather low occurrence of clinically
documented atherosclerosis (15%) and a low prevalence of traditional cardiovascular risk fac-
tors. Participants had preserved renal function, with a GFR of 91 (±28.1) ml/min/1.73m2 and
only 11% had CKD, as defined by the KDIGO criteria. A total of 13% had suffered a previous
cardiovascular event at any time-point before the baseline measurement.
Dividing the cohort in tertiles of T50 resulted in three groups of patients with similar char-
acteristics with regards to demographics, medication and main clinical parameters (Table 1).
Concerning laboratory parameters, descending T50 tertiles (i.e, reflecting increasing serum cal-
cification propensity) were associated with increasing prevalence of proteinuria (on 24-hours
urine collection) and hematuria, and with decreasing levels of hemoglobin, serum protein and
albumin, serum creatinine and C3 complement. Systemic corticosteroids were the most com-
mon treatment regimen in our cohort.
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Determinants of serum calcification propensity score (T50)
Univariate linear modeling showed that only hemoglobin, serum protein, albumin, creatinine
and C3 complement levels were significantly associated with T50 levels (Table 2). After multi-
variate modeling, serum T50 levels remained associated with hemoglobin, serum creatinine
and serum protein levels, explaining 43% of the variation in T50 at baseline. Forcing the disease
activity marker SELENA-SLEDAI score into the model revealed a significant inverse associa-
tion between disease activity and T50 levels. Implementation of the organ damage marker
(SLICC-DI score) into the model showed a non-significant association between organ damage
and T50 levels (data not shown).
Serum calcification propensity score (T50) and cardiovascular events
At baseline 21 patients (13%) had clinically documented atherosclerosis in various vascular
beds. Table 3 depicts univariate association of several risk factors of atherosclerosis and of T50
with total cardiovascular events. T50 levels tended to be marginally associated with presence of
adverse cardiovascular events (OR 2.2 95% CI 0.9–5.8 per 1 SD change; p = 0.099). Of interest,
T50 levels remained–albeit marginally significant- an independent predictor (OR 2 95% CI
0.9–4.4 per 1 SD change; p = 0.074) for prevalent cardiovascular disease in a multivariate
regression model (Table 3) that incorporated all significant confounders (p = 0.100).
Sensitivity analysis: T50 and disease activity
Given the association between T50 and disease activity, a subgroup-analysis was performed.
Based on clinically definitions SELENA-SLEDAI 4 was considered active SLE, whereas a
score <4 was considered inactive disease [20]. T50 showed no difference (p = 0.104) between
the subgroup of SLE patients with inactive (T50 median (IQR) levels; 303 (66) min.) or active
Fig 1. Distribution of serum calcification propensity score in SLE patients. Histogram of serum calcification
propensity score (T50) distribution in SLE patients (Kurtosis 1.252, Skewness -0.623). Q1, Q2 and Q3 represent tertiles
of T50 values.
https://doi.org/10.1371/journal.pone.0188695.g001
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Table 1. Baseline characteristics at enrollment in the study cohort.
Characteristic Overall (n = 168) Low tertile (n = 54) Intermediate tertile (n = 57) High tertile (n = 57) P value†
Demographics
Age (years) 43±14 44±16 40±13 46±14 0.02
Female/ Male 142/26 43/11 48/9 51/6 0.35
Race n (%) 0.37
Caucasian 130 (77%) 37 (69%) 48 (84%) 45 (79%)
African 15 (9%) 7 (13%) 3 (5%) 5 (9%)
Asian 17 (10%) 8 (15%) 4 (7%) 5 (9%)
Native American 3 (2%) 2 (4%) 1 (2%) 0
Obese or overweight (BMI25 kg/m2) 48 (35%) 19 (40%) 15 (32%) 14 (33%) 0.65
SLE Characteristics
Disease duration (years) 7 (11) 6 (9) 6 (14) 8 (14) 0.67
Age at diagnosis (years) 31 (23) 33 (24) 28 (21) 33 (24) 0.05
ACR criteria (points) 5 (2) 5 (1) 5 (1) 5 (2) 0.52
SELENA-SLEDAI Score (points) 4 (7) 5 (13) 4 (8) 4 (7) 0.14
Proteinuria (>0.5g/24h) n,(%) 22 (13%) 14 (26%) 7 (12%) 1 (2%) <0.001
Hematuria n, (%) 26 (16%) 14 (26%) 5 (9%) 7 (12%) 0.008
SLICC-DI (points) 0 (1) 0 (2) 0 (1) 0 (1) 0.41
Atherosclerosis Risk Factors
Diabetes Mellitus n,(%) 8 (5%) 4 (7%) 1 (2%) 3 (5%) 0.36
Hypertension n,(%) 59 (35%) 23 (43%) 18 (32%) 18 (32%) 0.37
Current Smoking n,(%) 39 (23%) 11 (20%) 14 (25%) 14 (25%) 0.83
Dyslipidemia n,(%) 25 (15%) 9 (17%) 7 (12%) 9 (16%) 0.78
Chronic Kidney Disease n,(%) ‡ 19 (11%) 8 (15%) 8 (14%) 3 (5%) 0.20
Cardiovascular Events at Baseline
Coronary Artery Disease (%) 9 (5%) 4 (7%) 1 (2%) 4 (7%) 0.38
Cerebrovascular Disease (%) 11 (7%) 3 (6%) 5 (9%) 3 (5%) 0.60
Peripheral Arterial Disease (%) 3 (2%) 1 (2%) 0 2 (4%) 0.19
Atherosclerosis in all vascular beds (%) 21 (13%) 8 (15%) 6 (11%) 7 (13%) 0.81
Cardiovascular History
Previous Myocardial Infarction (%) 4 (2%) 2 (4%) 1 (2%) 1 (2%) 0.75
Chronic Heart Failure (%) 2 (1%) 1 (2%) 0 1 (2%) 0.56
DVT / PE (%) 11 (7%) 6 (13%) 4 (7%) 1 (2%) 0.11
Laboratory Values
Erythrocyte sedimentation rate (1st hour) 15 (28) 22 (47) 12 (21) 17 (27) 0.09
Hemoglobin (g/l) 128 (25) 124 (28) 129 (24) 129 (19) 0.008
Serum creatinine (umol/l) 68 (22) 75 (35) 67 (19) 64 (21) 0.012
GFR (ml/min/1.73m2) 91 (28) 91 (48) 95 (35) 99 (31) 0.29
Serum protein (g/l) 72 (8) 69 (13) 73 (9) 73 (8) 0.004
Serum albumin (g/l) 38 (6) 35 (10) 39 (6) 40 (8) <0.001
Complement C3 (mg/dl) 0.84 (0.43) 0.72 (0.39) 0.87 (0.42) 0.94 (0.35) 0.016
Complement C4 (mg/dl) 0.14 (0.1) 0.13 (0.09) 0.16 (0.09) 0.14 (0.1) 0.19
Proteinuria (24h collection, g/l) 0.15 (0.90) 0.65 (1.5) 0.15 (2.2) 0.1 (0.18) 0.40
Medications
Systemic corticosteroids n,(%) 88 (52%) 34 (63%) 26 (46%) 28 (49%) 0.15
Immunosuppressants n,(%) 61 (36%) 24 (44%) 22 (39%) 15 (26%) 0.12
Other immunomodulators n,(%) 3 (2%) 1 (2%) 2 (4%) 0 0.24
(Continued)
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disease (T50 median (IQR); 291 (80) min.). Furthermore, distribution of active or inactive dis-
ease was similar across the tertiles of T50 (low tertile: 33% inactive vs 67% active; intermediate
tertile: 44% inactive vs. 56% active; high tertile: 47% inactive vs. 53% active; χ2-test, P = 0.298).
However, when considering only patients with active disease (SELENA-SLEDAI score4;
n = 98) we found a significant negative association between T50 and SELENA-SLEDAI score at
baseline (Spearman’s rho -0.233, P = 0.021). In contrast, in SLE patients with inactive disease
(SELENA-SLEDAI score <4; n = 70), no significant association between baseline T50 and
SELENA-SLEDAI score was found (Spearman’s rho -0.051, P = 0.675) and summarized in
S1 Fig.
In order to explore the impact of mild disease activity, we performed a subgroup-analysis
considering SELENA-SLEDAI >0 as active and a score of 0 as inactive SLE disease. T50
showed no difference (p = 0.414) between the subgroup of SLE patients with inactive (n = 37;
T50 median (IQR) levels; 301 (65) min.) or active disease (n = 131; T50 median (IQR); 292 (69)
min. However, when considering only patients with active disease (SELENA-SLEDAI score
Table 1. (Continued)
Characteristic Overall (n = 168) Low tertile (n = 54) Intermediate tertile (n = 57) High tertile (n = 57) P value†
NSAIDs n,(%) 24 (14%) 8 (15%) 6 (11%) 10 (18%) 0.82
Values are presented as mean values ± standard deviation or median values with (interquartile range) for continuous variables or as percentages for categorical variables.
BMI, body mass index; SLE, systemic lupus erythematosus; ACR, American College of Rheumatology; SELENA-SLEDAI, Safety of Estrogen in Lupus Erythematosus
National Assessment–Systemic Lupus Erythematosus Disease Activity Index; SLICC-DI, Systemic Lupus International Collaborative Clinics- Damage Index; DVT Deep
Vein thrombosis; PE, Pulmonary Embolism; GFR, glomerular filtration rate; NSAIDs, non-steroid anti-inflammatory drugs.
 P value was considered as significant <0.016 for correction for multiple comparisons
† P value was calculated by one-way ANOVA test for continuous variables with normal distribution, Kruskal-Wallis test for continuous variables with non-normal
distribution and chi-squared test for categorical variables
‡ CKD defined as eGFR < 60 m/min
https://doi.org/10.1371/journal.pone.0188695.t001
Table 2. Determinants of serum calcium propensity score (T50) in univariate, multivariate linear regression analyses and in forced model using SELENA-SLEDAI
score.
T50
Univariate model Multivariate model Forced model
Variable a SD increment β value b (95%CI) P value β value b (95%CI) P value β value b (95%CI) P value
Proteinuria (>0.5g/24h) n/a 0.1 (-0.2 to 0.4) 0.58 - - - -
Hematuria n/a 0.4 (-0.1 to 0.8) 0.08 - - - -
Hemoglobin (g/l) 17.8 37 (22 to 51) <0.001 26 (3 to 48) 0.02 -24 (-42 to -0.7) 0.007
Serum Creatinine (μmol/l) 35.3 -31 (-46 to -17) <0.001 -18 (-36 to -0.1) 0.04 37 (14 to 61) 0.002
Serum Protein (g/l) 7.9 55 (37 to 73) <0.001 42 (18 to 65) 0.001 - c - c
Serum Albumin (g/l) 7.2 57 (41 to 74) <0.001 - c - c - -
Complement C3 (mg/dl) 0.28 24 (6 to 42) 0.01 - - - -
SELENA-SLEDAI score (points) 8 -70 (-118 to -21) 0.006
a Only baseline variables that were different between the 3 tertiles of serum T50 (P<0.016) were analyzed.
b Per 1 SD increase in each continuous independent variable
c Due to increased co linearity between serum protein and serum albumin levels, the variable which conferred better to the R2 value was selected (i.e. serum protein
levels)
All continuous variables were divided by their corresponding standard deviation in order to achieve normal distribution. SELENA-SLEDAI; Safety of Estrogen in Lupus
Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index
https://doi.org/10.1371/journal.pone.0188695.t002
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>0; n = 131) we found a pronounced negative association between T50 and SELENA-SLEDAI
score at baseline (Spearman’s rho -0.219, P = 0.012).
Sensitivity analysis: Clinical and demographic subgroups
Sensitivity analysis of demographics revealed that the observed inverse correlation between
serum calcification propensity score (T50) and disease activity (SELENA-SLEDAI score) was
associated with male sex (Spearman’s rho -0.174; p = 0.039), obesity (BMI 25 kg/m2; Spear-
man’s rho -0.344; p = 0.017), GFR< 60ml/min/1.73 m2 (Spearman’s rho -0.521; p = 0.009),
diabetes mellitus (Spearman’s rho -0.854; p = 0.007), hypertension (Spearman’s rho -0.345;
p = 0.008), non-smoking status (Spearman’s rho -0.148; p = 0.017), and the absence of dyslipi-
demia (Spearman’s rho -0.165; p = 0.048) (Table 4).
Discussion
Cardiovascular disease is one of the major causes of morbidity and mortality in SLE. The T50-
value is a novel integrated functional measure of calcification propensity in human blood
(serum), which may mechanistically link cardiovascular risk and vascular damage with SLE
disease activity. The present study explored for the first time a potential association between
Table 3. Univariate and multivariate association of known predictors of atherosclerotic disease and serum calcification propensity score (T50) at baseline with total
cardiovascular events.
Variable a Total Cardiovascular Events
Univariate Multivariate
ORsb (95%CI) P value ORsb (95%CI) P value
Age (years) 2 (1.3–3.1) 0.003
Obese or overweight (BMI25 kg/m2) 1.6 (0.5–4.5) 0.41
Diabetes mellitus 4.6 (1–21) 0.04
Dyslipidemia 7.8 (2.9–21.5) <0.001 8.9 (2–39.5) 0.004
Hypertension 4.6 (1.7–12) 0.002
Smoking 1.8 (0.7–4.7) 0.26
Chronic Kidney Disease 2.9 (0.9–9.1) 0.06
Disease duration (months) 1.6 (1.1–2.4) 0.01
SELENA-SLEDAI (points) 1.8 (0.7–4.5) 0.19
SLICC-DI score (points) 4.7 (2.7–8.3) <0.001 5.3 (2.5–11.3) <0.001
GFR (ml/min/1.73m2) 0.9 (0.5–1.4) 0.51
Systemic corticosteroids 3.5 (1.2–10) 0.02
Lipid Lowering Drugs 5 (1.7–14.7) 0.003
ACE-inhibitors 0.2 (0.1–0.6) 0.005
AT-receptor blockers 0.6 (0.1–3) 0.54
B-blockers 0.2 (0.1–0.6) 0.005
Antithromboticsc 0.1 (0.1–0.2) <0.001 0.1 (0.1–0.5) 0.004
Serum T50 2.2 (0.9–5.8) 0.09 2 (0.9–4.4) 0.07
a In the multivariate model all baseline variable with P<0.100 were included.
b Per 1 SD increase in each continuous independent variable (age, 14 years; disease duration, 9.2 months; SELENA-SLEDAI score, 8 points, SLICC-DI score, 2 points;
serum/plasma creatinine, 35.3 umol/L; GFR, 27.8 ml/min/1.73m2; Total Cholesterol, 1.26 mmol/L; LDL cholesterol, 1.02 mmol/L; HDL cholesterol, 0.49 mmol/L;
Triglycerides, 1.29 mmol/L; T50, 63 min)
c Antithrombotic therapy included antiplatelet, oral anticoagulant, or low weight molecular weight heparin
BMI, Body Mass Index; SELENA-SLEDAI, Safety of Estrogen in Lupus Erythematosus National Assessment; Systemic Lupus Erythematosus Disease Activity Index;
SLICC-DI, Systemic Lupus International Collaborative Clinics- Damage Index; GFR, glomerular filtration rate; ACE, Angiotensin Converting Enzyme; AT, angiotensin.
https://doi.org/10.1371/journal.pone.0188695.t003
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T50 and SLE activity in a cohort of relatively young SLE patients. As our main finding we dem-
onstrated that low serum T50 was associated with SELENA-SLEDAI score, in particular in
patients with active lupus disease.
T50 quantifies the overall calcification-propensity, by timing the spontaneous transforma-
tion of spherical primary calciprotein particles (CPPs) to spindle-shaped, stabilized secondary
CPPs, which contain crystalline calcium phosphate [14]. In our study, several parameters, such
as low hemoglobin, increased serum creatinine and low serum protein levels, were signifi-
cantly associated with T50 levels. All these factors reflecting disease activity and indirectly sys-
temic inflammation, explain after multivariate modeling 43% of the variation of T50 level at
baseline. Analogously, Smith et al found in their cohort of patients with mild to moderate
CKD an association between lower serum T50 values and higher concentrations of the inflam-
matory markers hsCRP and TNF-α [15]. Experimental models demonstrate that secondary
CPP provoke proinflammatory responses in murine macrophages [21] and also in vascular
smooth muscle cells by stimulating the release of TNF-α [22], relating the correlation of T50
Table 4. Interaction effects of various clinical and demographic variables on the observed association between serum calcification propensity score (T50) and disease
activity (SELENA-SLEDAI).
Variable Spearman’srho P value Fisher’s z-test P value for Interaction
Male -0.174 0.03 0.335 0.73
Female -0.246 0.22
Age <70 years -0.153 0.05 1.217 0.22
Age70 years -0.609 0.10
Low GFR <60 min/min/1.73m2 -0.521 0.009 1.962 0.04
High GFR 60 ml/min/1.73m2 -0.115 0.18
No Albuminuria (<0.3 g/l) -0.015 0.95 0.631 0.52
Albuminuria (0.3 g/l) -0.299 0.47
Low LDL cholesterol (<100 mg/dl) -0.097 0.62 0.679 0.49
High LDL cholesterol (100 mg/dl) -0.298 0.19
Low SBP (<135mmHg) -0.123 0.24 1.088 0.27
High SBP (135mmHg) -0.379 0.08
No Diabetes Mellitus -0.143 0.07 2.480 0.01
Diabetes Mellitus -0.854 0.007
No Dyslipidemia -0.165 0.04 0.332 0.73
Dyslipidemia -0.238 0.25
No Hypertension -0.061 0.53 1.808 0.07
Hypertension -0.345 0.008
No Smoking -0.210 0.01 0.474 0.63
Smoking -0.123 0.45
No Chronic Kidney Disease -0.148 0.07 0.865 0.38
Chronic Kidney Disease -0.360 0.13
No obesity (BMI < 25 Kg/m2) -0.090 0.40 1.456 0.14
Obesity (BMI 25 Kg/m2) -0.344 0.01
SELENA-SLEDAI, Safety of Estrogen in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index; GFR, glomerular filtration
rate; LDL, Low Density Lipoprotein; SBP, Systolic Blood Pressure; BMI, Body Mass Index. Subsequent analysis for interaction showed that GFR <60 ml/min/1.73m2,
diabetes mellitus, and hypertension significantly influenced the inverse association between serum calcification propensity T50 score and disease activity (Table 4).
Multivariate analysis in a model of all possible interaction terms (diabetes mellitus, hypertension, GFR levels) revealed that serum calcification propensity score (T50)
continued to be inversely associated with disease activity as described by SELENA-SLEDAI score (beta value -86 95% CI -126 to -46 per 1 SD change (8 points) of
SELENA-SLEDAI score; p<0.001).
https://doi.org/10.1371/journal.pone.0188695.t004
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with inflammation. After integrating the disease activity marker SELENA-SLEDAI score into
the model, a significant inverse association between disease activity and T50 levels was revealed.
Of interest, this significant inverse association can still be found considering mild disease
activity. These observations support our hypothesis that humoral mineralization imbalances
may play a pathogenic role in premature cardiovascular in SLE.
Although there were a low incidence of atherosclerosis and previous cardiovascular events
in our cohort, T50 levels were a near-significant independent predictor for cardiovascular dis-
ease. In our study, traditional cardiovascular risk factors (i.e. age, sex, dyslipidemia or smok-
ing) were not identified as determinants of T50 in regression analysis. Our results open the
possibility that calcification propensity may represent a non-traditional cv-risk factors impor-
tant not only for renal patients but also for patients suffering from chronic inflammatory dis-
eases, which are of note also associated with increased levels of endogenous calciprotein
particles [23]. Data from animal models suggest that the vascular endothelium in SLE is more
prone to inflammation [24]. Similarly, disease activity, longer duration of disease, higher dam-
age-index score and less aggressive immunosuppressive therapy were shown to be important
determinants of accelerated atherosclerosis in SLE [1, 6, 7, 25–27], suggesting a potential ath-
erogenic effect of inflammation in SLE. Nevertheless no significant correlation between
inflammatory markers—such as CRP, interleukin-6 or tumor necrosis factor—and accelerated
atherosclerosis in SLE were found [1, 2, 7, 25, 26]. The factors responsible for accelerated ath-
erosclerosis in SLE patients seem to be more complex and difficult to be determined by the
measurement of a single molecule. This is not entirely surprising since the mechanisms driving
mineralization are multifactorial and dependent on a balance between calcification inhibitors
and promoters. Given that T50 is a functional test of the all over capacity of calcification, differ-
ent factors influencing the process of calcification are taken into account, whether these factors
inhibit or promote calcification or whether these factors are known or not yet known. The T50
value may therefore provide an important tool linking inflammation, disease activity and
accelerated atherosclerosis to the pronounced cardiovascular morbidity and mortality of SLE
patients.
Our results support the proposed interplay of non-traditional and lupus-specific risk factors
in the development of premature atherosclerosis driven by impaired “bio-mineralization”.
Cardiovascular events and vascular calcification in multiple vascular beds are more prevalent
in SLE that in age-matched subjects of the general population [4, 5]. In previous reports the
risk of vascular calcification in patients with SLE was 33.6 fold higher than control subjects
after adjusting for age and sex. Also in a cohort of 139 young lupus patients (93% females),
which was screened for coronary artery calcifications Juanita Romero-Dıaz and colleagues
found an association of coronary artery calcifications with increased disease activity along the
course of lupus [28]. In accordance with previous findings, in our study cohort coronary artery
calcification was already present despite the patients’ young age. Several studies suggest that
treatment of disease activity with antimalarial drugs reduces atherosclerosis and thrombosis in
SLE patients [1, 29–31]. The results of our study are in accordance with previous findings indi-
cating that the T50 value may represent a composite of non-traditional cardiovascular risk fac-
tors and has already shown discriminatory ability concerning cardiovascular events in various
patient cohorts. Increased serum calcification propensity (i.e., lower serum T50) was a potent
predictor and risk factor of all-cause and cardiovascular mortality in long-term renal trans-
planted patients, which substantially improved mortality prognostication [17]. Also in a pro-
spective cohort of 184 patients with stages 3 and 4 CKD and a follow-up time over 5 years, the
lowest T50 tertile had in the fully adjusted multivariate analysis more than twice elevated mor-
tality risk in comparison to patients in the highest T50 tertile [15].
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Numerous established laboratory tests such as vitamin D receptors, interferon signature,
urinary interleukin (IL)-6, and complement activation markers, assessing disease activity have
been reported. However, their utility is limited because they are mainly experimental and not
accessible for routine clinical care. Additionally they do not assess the risk for accelerated ath-
erosclerosis due to disease activity. In our cohort we observed a significant association of
higher serum calcification propensity at baseline with disease activity. Therefore, calcification
propensity might bear the potential to routinely identify SLE patients with potential higher
burden of cardiovascular disease and elevated risk due to non-traditional cardiovascular risk
factors.
Our demonstration that T50 is closely associated with established non-traditional risk fac-
tors and reflects the patients’ previous cardiovascular morbidity is an important step towards a
better understanding of the pathophysiological mechanisms involved in cardiovascular events
in patients with SLE.
Our study is subject to limitations inherent to the observational nature of a registry dataset
collected prospectively. The distribution curve of SELENA-SLEDAI score measurements at
baseline shows a slight deviation to the right suggesting that the activity score is measured
within a population with average low disease activity, minor organ damage and low prevalence
of cardiovascular risk factors, limiting the generalizability of our findings to patients with
more severe SLE manifestations and comorbidities. The study size did not have adequate sta-
tistical power to prove prognosis associations. Nevertheless, our findings provide important
hints for an association with CV prognosis. Most of our subjects were Caucasian women,
which limits the application of our findings to men and other ethnic backgrounds. Although a
multitude of demographic, clinical, and disease related variables were adjusted in our multi-
variate analyses, as with all observational studies, it is possible that unmeasured confounders
may have influenced our results.
In conclusion, this is the first study to demonstrate an association between lower T50 and
disease activity. Moreover, T50 levels identify a subgroup of SLE patients with ongoing sys-
temic inflammation as mirrored by increased disease activity. Notably, all of these relation-
ships persisted even after adjustment for other biomarkers and comorbidities. Based on these
findings, we postulate that T50 could be a promising biomarker reflecting SLE disease activity
and might offer an earlier detection tool for high-risk patients with non-traditional cardiovas-
cular risk factors. Additional studies are needed to corroborate these findings and guide the
implementation of T50 in cardiovascular preventive strategies and aggressive management in
selected SLE patients.
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